论文部分内容阅读
目的观察奥扎格雷钠联合小牛血清去蛋白注射液治疗急性脑梗死的疗效及安全性。方法 160例急性脑梗死患者,随机分为观察组(80例)和对照组(80例),在常规治疗的基础上,观察组采用奥扎格雷钠注射液联合小牛血清去蛋白注射液治疗,对照组仅奥扎格雷钠注射液治疗,两组疗程均14d,观察两组治疗前及治疗14d后NIHSS评分,ADL评分和临床疗效变化。结果观察组患者的NIHSS,ADL评分均有明显改善,临床有效率达90.00%,高于对照组的72.50%(P<0.05)。结论奥扎格雷钠联合小牛血清去蛋白注射液治疗急性脑梗死疗效明确,未见明显不良反应,并能更好地控制脑梗死的进展,值得临床推广应用。
Objective To observe the efficacy and safety of sodium ozagrel combined with bovine serum albumin in the treatment of acute cerebral infarction. Methods One hundred and sixty patients with acute cerebral infarction were randomly divided into observation group (80 cases) and control group (80 cases) .On the basis of routine treatment, the observation group was treated with sodium ozagrel and bovine serum albumin injection , The control group was treated with ozagrel sodium only. The duration of treatment was 14 days. The changes of NIHSS score, ADL score and clinical curative effect before and 14 days after treatment were observed in both groups. Results The scores of NIHSS and ADL in the observation group were all significantly improved. The clinical effective rate was 90.00%, which was higher than that of the control group (72.50%, P <0.05). Conclusion Ozagrel combined with bovine serum deproteinized injection for the treatment of acute cerebral infarction has a clear effect, no obvious adverse reactions, and can better control the progress of cerebral infarction, which is worthy of clinical application.